CD8A and neoplasm: To probe the clinical relevance of this hypothetical defect in antitumor T cell dysfunction amongst RCC patients, we investigated the genomic profile of tumor-reactive CD8+ T cells obtained after extended rounds of MLTC stimulation with an highly immunogenic RCC cell line (patient TC) and compared with their HLA-matched healthy donors (donor 2 and 3).